0.477
3.61%
0.0166
前日終値:
$0.4604
開ける:
$0.479
24時間の取引高:
28,696
Relative Volume:
0.08
時価総額:
$6.53M
収益:
$122.10K
当期純損益:
$-13.77M
株価収益率:
-0.6276
EPS:
-0.76
ネットキャッシュフロー:
$-4.79M
1週間 パフォーマンス:
+10.93%
1か月 パフォーマンス:
-14.82%
6か月 パフォーマンス:
-55.00%
1年 パフォーマンス:
-20.23%
Ainos Inc Stock (AIMD) Company Profile
AIMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AIMD
Ainos Inc
|
0.477 | 6.53M | 122.10K | -13.77M | -4.79M | -0.76 |
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Ainos Inc (AIMD) 最新ニュース
Ainos, Inc. Reports Q3 Financial Results and Strategic Developments - TipRanks
AIMD Stock Hits 52-Week Low at $0.4 Amid Market Challenges - Investing.com India
AIMDAinos, Inc. Latest Stock News & Market Updates - StockTitan
Ainos (AIMD) Advances VELDONA Trial for Sjogren's: Key IRB Approval Secured, 28 Patents Added | AIMDW Stock News - StockTitan
Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest - Defense World
Ainos Advances Sjögren's Treatment: Key Trial for VELDONA® Gets IRB Green Light | AIMDW Stock News - StockTitan
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) - Yahoo Finance
Ainos reports unusual stock activity to regulators - Investing.com India
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - WICZ
Ainos reports unusual stock activity to regulators By Investing.com - Investing.com UK
Ainos (AIMD) Alerts SEC to Suspicious Trading Activity, Demands Investigation | AIMDW Stock News - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 14.7% – Here’s Why - Defense World
Ainos Reports Third Quarter 2024 Financial Results - StockTitan
Behcet's syndrome Treatment Market 2034: Clinical Trials, EMA, - openPR
Ainos stock plunges to 52-week low of $0.45 amid steep annual decline - Investing.com
Analyzing CONMED (NYSE:CNMD) & Ainos (OTCMKTS:AIMD) - Defense World
Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 37.6% in October - Defense World
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets - StockTitan
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - StockTitan
Ainos Inc. secures exclusive patent rights in new deal - Investing.com
Ainos Inc. secures exclusive patent rights in new deal By Investing.com - Investing.com UK
Ainos (OTCMKTS:AIMD) Stock Price Down 8.7% – Here’s Why - Defense World
Ainos Leverages AI Nose for Safer, Smarter Factories - MSN
Financial Health Report: Ainos Inc (AIMD)’s Ratios Tell a Tale - The Dwinnex
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges - GuruFocus.com
Ainos Inc. secures stockholder nod for special stock awards - Investing.com
Ainos planning Phase 3 study of low-dose interferon-alpha for primary Sjögren’s - Sjogren's Syndrome News
AIMDWAinos, Inc. Warrants Latest Stock News & Market Updates - StockTitan
Ainos Inc (AIMD) Stock: A Year of Highs and Lows - The InvestChronicle
Ainos receives IRB nod for HIV-related oral wart trial - Investing.com India
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - StockTitan
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome - StockTitan
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options - StockTitan
Esperion Therapeutics (NASDAQ:ESPR) versus Ainos (NASDAQ:AIMD) Critical Analysis - Defense World
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts - StockTitan
AIMD stock touches 52-week low at $0.45 amid market challenges - Investing.com
Ainos set for clinical trial of HIV treatment at Taiwan hospital - Investing.com
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA - StockTitan
Financial Review: Ainos (OTCMKTS:AIMD) versus Siemens Healthineers (OTCMKTS:SMMNY) - Defense World
Ainos (NASDAQ:AIMD) Shares Down 6.6% - Defense World
Ainos secures Taiwan patent for antiviral drug VELDONA - Investing.com
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention - Lelezard
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 6.1% - Defense World
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter - PharmiWeb.com
Ainos Inc (AIMD) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Is the Ainos Inc (NASDAQ:AIMD) stock an investment opportunity? - US Post News
Ainos AI Nose achieves 79% accuracy in VOC detection - Investing.com India
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - AccessWire
Ainos Inc (AIMD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):